cGMP Phosphodiesterases (cGMP PDEs) As Therapeutic Targets in Cancer

authors:

avatar Ramin Saravani ORCID 1 , * , avatar Hamid Reza Galavi 1

Cellular and Molecular Research Center and Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
Gene, Cell and Tissue: Vol.4, issue 2; e12336
published online: April 30, 2017
article type: Letter
received: April 22, 2017
accepted: April 29, 2017
DOI: https://doi.org/10.5812/gct.12336

how to cite: Saravani R, Galavi H R. cGMP Phosphodiesterases (cGMP PDEs) As Therapeutic Targets in Cancer. Gene Cell Tissue. 2017;4(2):e12336. https://doi.org/10.5812/gct.12336.

References

  • 1.

    Rehmann H, Wittinghofer A, Bos JL. Capturing cyclic nucleotides in action: snapshots from crystallographic studies. Nat Rev Mol Cell Biol. 2007;8(1):63-73. [PubMed ID: 17183361]. https://doi.org/10.1038/nrm2082.

  • 2.

    Omori K, Kotera J. Overview of PDEs and their regulation. Circ Res. 2007;100(3):309-27. [PubMed ID: 17307970]. https://doi.org/10.1161/01.RES.0000256354.95791.f1.

  • 3.

    Saravani R, Galavi HR, Shahraki A. Inhibition of Phosphodiesterase 5 and Increasing the Level of Cyclic Guanosine 3',5' Monophosphate by Hydroalcoholic Achillea wilhelmsii C. Koch Extract in Human Breast Cancer Cell Lines MCF-7 and MDA-Mb-468. Breast Cancer (Auckl). 2017;11:1178223417690200. [PubMed ID: 28469435]. https://doi.org/10.1177/1178223417690178.

  • 4.

    Das A, Durrant D, Salloum FN, Xi L, Kukreja RC. PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacol Ther. 2015;147:12-21. [PubMed ID: 25444755]. https://doi.org/10.1016/j.pharmthera.2014.10.003.

  • 5.

    Karami-Tehrani F, Moeinifard M, Aghaei M, Atri M. Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors. Arch Med Res. 2012;43(6):470-5. [PubMed ID: 22960860]. https://doi.org/10.1016/j.arcmed.2012.08.006.

  • 6.

    Sarfati M, Mateo V, Baudet S, Rubio M, Fernandez C, Davi F, et al. Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. Blood. 2003;101(1):265-9. [PubMed ID: 12393651]. https://doi.org/10.1182/blood-2002-01-0075.

  • 7.

    Zhu B, Vemavarapu L, Thompson WJ, Strada SJ. Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J Cell Biochem. 2005;94(2):336-50. [PubMed ID: 15526282]. https://doi.org/10.1002/jcb.20286.

  • 8.

    Liu L, Underwood T, Li H, Pamukcu R, Thompson WJ. Specific cGMP binding by the cGMP binding domains of cGMP-binding cGMP specific phosphodiesterase. Cell Signal. 2002;14(1):45-51. [PubMed ID: 11747988]. https://doi.org/10.1016/S0898-6568(01)00216-9.

  • 9.

    Saravani R, Karami-Tehrani F, Hashemi M, Aghaei M, Edalat R. Inhibition of phosphodiestrase 9 induces cGMP accumulation and apoptosis in human breast cancer cell lines, MCF-7 and MDA-MB-468. Cell Prolif. 2012;45(3):199-206. [PubMed ID: 22469131]. https://doi.org/10.1111/j.1365-2184.2012.00819.x.

  • 10.

    Li N, Xi Y, Tinsley HN, Gurpinar E, Gary BD, Zhu B, et al. Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/beta-catenin signaling. Mol Cancer Ther. 2013;12(9):1848-59. [PubMed ID: 23804703]. https://doi.org/10.1158/1535-7163.MCT-13-0048.